Royalty Pharma (RPRX) Current Assets (2019 - 2026)
Royalty Pharma (RPRX) posted Current Assets of $1.4 billion for Q1 2026, down 6.69% sequentially from $1.5 billion in Q4 2025, and down 22.65% YoY from $1.8 billion in Q1 2025.
Royalty Pharma (RPRX) Current Assets (2019 - 2026) Analysis & Trends
Royalty Pharma has reported Current Assets for 8 years, with the latest figure at $1.4 billion in Q1 2026.
- Quarterly Current Assets fell 22.65% year-over-year to $1.4 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.4 billion (down 22.65% YoY) and the FY2025 annual result came in at $1.5 billion, down 15.21% from the prior year.
- Current Assets fell to $1.4 billion in Q1 2026 per RPRX's latest filing, from $1.5 billion in the prior quarter.
- Over five years, Current Assets peaked at $3.5 billion in Q2 2022 and troughed at $1.3 billion in Q4 2023.
- A 5-year average of $2.1 billion and a median of $1.8 billion in 2025 frame the typical range for Current Assets.
- The sharpest annual moves came in 2023 and 2024: Current Assets slumped 50.13% in 2023, then jumped 41.43% in 2024.
- Over 5 years, Current Assets stood at $2.6 billion in 2022, then plunged by 50.13% to $1.3 billion in 2023, then soared by 41.43% to $1.8 billion in 2024, then decreased by 15.21% to $1.5 billion in 2025, then declined by 6.69% to $1.4 billion in 2026.
- According to Business Quant data, Current Assets over the past three periods registered $1.4 billion, $1.5 billion, and $1.8 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 4.74 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.76 Bn |
| Mar 31, 2026 | 1.43 Bn |
| Dec 31, 2025 | 1.53 Bn |
| Sep 30, 2025 | 1.85 Bn |
| Jun 30, 2025 | 1.52 Bn |
| Mar 31, 2025 | 1.84 Bn |
| Dec 31, 2024 | 1.80 Bn |
| Sep 30, 2024 | 1.79 Bn |
| Jun 30, 2024 | 2.58 Bn |
| Mar 31, 2024 | 1.56 Bn |
| Dec 31, 2023 | 1.27 Bn |
| Sep 30, 2023 | 1.73 Bn |
| Jun 30, 2023 | 2.95 Bn |
| Mar 31, 2023 | 2.63 Bn |
| Dec 31, 2022 | 2.55 Bn |
| Sep 30, 2022 | 2.34 Bn |
| Jun 30, 2022 | 3.50 Bn |
| Mar 31, 2022 | 2.98 Bn |
| Dec 31, 2021 | 2.88 Bn |
| Sep 30, 2021 | 2.78 Bn |